NCT05992831 (PUSH2) is a NA clinical trial of Accelerated iTBS in Mild Cognitive Impairment, sponsored by Medical University of South Carolina.

Who is sponsoring NCT05992831?

NCT05992831 is sponsored by Medical University of South Carolina.

What drugs are being tested in NCT05992831?

Interventions in NCT05992831: Accelerated iTBS, Sham Comparator.

What condition does NCT05992831 study?

NCT05992831 studies Mild Cognitive Impairment, Depression.

Is NCT05992831 still recruiting?

NCT05992831 is currently recruiting now. Last updated 2 April 2026.

Last reviewed 2026-04-02 · How we verify

NCT05992831: PUSH2

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Transcranial Magnetic Stimulation for MCI

Recruiting now NA Last updated 2 April 2026

What this trial tests

NA trial testing Accelerated iTBS in Mild Cognitive Impairment in 60 participants. Currently enrolling.

Timeline

18 June 2024

Primary endpoint
30 April 2028

30 April 2028

Quick facts

Lead sponsor	Medical University of South Carolina
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	60
Start date	18 June 2024
Primary completion	30 April 2028
Estimated completion	30 April 2028
Sites	1 location across United States

Drugs / interventions tested

Accelerated iTBS
Sham Comparator

Conditions studied

Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →
Depression — all drugs for Depression →

Sponsor

Medical University of South Carolina

Who can join

Adults 60 to 85, any sex, with Mild Cognitive Impairment or Depression. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this phase II study is to establish the dose-response curves of a safe and clinically feasible non-invasive brain stimulation technique (accelerated Transcranial Magnetic Stimulation (TMS)) to improve both depression and cognitive function in Mild Cognitive Impairment (MCI) patients with comorbid depression. It is known that TMS can effectively treat depression. Identifying the right dose of accelerated TMS in MCI patients is necessary prior to designing subsequent trials to determine efficacy. These results will inform future clinical trials of accelerated TMS for MCI, with the long-term goal of developing an efficacious treatment to prevent dementia.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

A phase I trial of accelerated intermittent theta burst rTMS for amnestic MCI.
Aghamoosa S, Lopez J, Rbeiz K, Fleischmann HH, et al · · 2024 · cited 7× · PMID 38719432 · DOI 10.1136/jnnp-2023-332680
Accelerated iTBS-Induced changes in resting-state functional connectivity correspond with cognitive improvement in amnestic MCI.
Aghamoosa S, Nolin SA, Chen AA, Caulfield KA, et al · · 2025 · cited 1× · PMID 40252967 · DOI 10.1016/j.brs.2025.04.012

Verify or expand the search:

Other trials of Accelerated iTBS

Trials testing the same drug.

NCT07526740 — Brain Stimulation and Cognitive Training for MCI · NA · recruiting
NCT07445620 — Comparison of Accelerated Intermittent Theta Burst Stimulation vs High Frequency Transcranial Magnetic Stimulation (Hf-r · NA · not yet recruiting
NCT06971549 — Accelerated iTBS for Depression: Monitoring Brain Hemodynamics With Simultaneous iTBS/fNIRS · NA · recruiting

Other recruiting trials for Mild Cognitive Impairment

Currently open trials in the same condition.

NCT05791994 — EVASION: Effect of VisuAl Stimulation on attentION · NA · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen · NA · recruiting
NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
NCT07318038 — The Use of Rhythmic Light Therapy in Mild Cognitive Impairment · NA · recruiting

Other Medical University of South Carolina trials

Trials by the same sponsor.

NCT06491264 — Multiparameter Optimized tES for Memory in Aging · NA · withdrawn
NCT07513389 — Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION) · Phase 2 · not yet recruiting
NCT03101917 — Microtable® Method for Cochlear Implantation Investigational Device Exemption (IDE) · NA · not yet recruiting
NCT07149207 — Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors · Phase 2 · recruiting
NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05992831 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of South Carolina
Last refreshed: 2 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05992831.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing